Actelion Ltd.
is a leading
biopharmaceutical
company focused
on the discovery,
development
and commercialization
of innovative drugs
for diseases
with significant
unmet medical needs.

Very strong performance in the first half of 2016

Jean-Paul Clozel, CEO: "We’ve had an excellent first half year, driven by the strong performance

of our outcome-based PAH products."

Jean-Paul Clozel, CEO: "We’ve had an excellent first half year, driven by the strong performance

of our outcome-based PAH products."

Global Actelion

Hotspot of possibilities

Actelion has subsidiaries in over 30 countries, covering all major pharmaceutical markets worldwide

Hotspot of possibilities

Actelion has subsidiaries in over 30 countries, covering all major pharmaceutical markets worldwide

Shareprice

ATLN SIX Swiss Exchange

Shareprice
At 13:13:07 CET 27/07/2016
CHF 174,30Up Down image
+0,70 (+0,40%)